TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
Transcenta’s manufacturing facility currently has multiple 200~2000L DS production lines and a fully automated drug product filling line with isolators, and reserved space for expansion of its production line. It is expected to have an annual capacity of over one ton (1,000 kg/year) in the future. In operation for 5 years up to the first quarter of 2023, this GMP production facility has 100% successfully undertaken more than fifty batches of internal and external projects.